Sports-related concussions (SRCs) are a major health issue in athletes of varying ages, ability levels, and sports. Concerns over the short- and long-term consequences of SRCs have incentivized a wealth of products and policies aimed at reducing SRC risk. Research suggesting the effectiveness of such interventions at reducing SRCs has facilitated their adoption by sports organizations and, in some cases, product commercialization. However, the body of SRC mitigation research is almost entirely devoid of placebo or sham groups, which raises important questions about the true clinical effectiveness of these interventions. This Current Opinion explores the plausibility of placebo effects within the scope of SRC prevention, describes why the lack of placebo/sham groups in the current body of literature is problematic, and provides recommendations for including placebo/sham groups in future SRC research. Key Points: Research examining the effectiveness of interventions designed to reduce the risk of sports-related concussions is universally conducted without blinding participants to the assigned intervention, or the inclusion of a placebo/sham group. Sports-related concussion diagnosis is heavily dependent on honest self-reporting of symptoms, and is likely to be sensitive to placebo effects. Future research examining sports-related concussion mitigation should include placebo/sham groups to better understand the true effectiveness of the interventions of interest.
© Copyright 2025 Sports Medicine. Springer. All rights reserved.